<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625974</url>
  </required_header>
  <id_info>
    <org_study_id>16027</org_study_id>
    <nct_id>NCT02625974</nct_id>
  </id_info>
  <brief_title>Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease</brief_title>
  <acronym>CHICO</acronym>
  <official_title>Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study consists of two parts. Part I was designed to develop a better understanding of the
      efficacy, safety and pharmacokinetics of nifurtimox in children with a diagnosis of Chagas'
      disease (Trypanosoma cruzi infection) using pediatric formulations. Part II was designed at
      request of the FDA to assess the incidence of sero-negative conversion in children with
      diagnosis of Chagas' disease treated with nifurtimox.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 27, 2016</start_date>
  <completion_date type="Anticipated">August 9, 2021</completion_date>
  <primary_completion_date type="Actual">July 25, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Cured</measure>
    <time_frame>At 12 months post-treatment</time_frame>
    <description>Cure is defined as sero-reduction (in subjects ≥8 months to &lt;18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a ≥20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.
Subjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).
For the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs from the two publications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate of Seronegative Conversion for Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.(Part 2)</measure>
    <time_frame>Up to 4 years after end of treatment</time_frame>
    <description>Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay [IHA]) in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1</measure>
    <time_frame>At Visit 1 (before treatment started)</time_frame>
    <description>The evaluation was based on clinical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3</measure>
    <time_frame>Up to 7 days (Visit 3)</time_frame>
    <description>The evaluation was based on clinical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6</measure>
    <time_frame>Up to 30 days (Visit 6)</time_frame>
    <description>The evaluation was based on clinical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8</measure>
    <time_frame>Up to 60 days (Visit 8) end of treatment</time_frame>
    <description>The evaluation was based on clinical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9</measure>
    <time_frame>Up to 90 days (Visit 9) post treatment</time_frame>
    <description>The evaluation was based on clinical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10</measure>
    <time_frame>Up to 240 days (Visit 10) post treatment</time_frame>
    <description>The evaluation was based on clinical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The evaluation was based on clinical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects &lt;8 Months of Age)</measure>
    <time_frame>Up to 90 days (Visit 9) post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin β, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Clinical significance of abnormal ECG was based on the judgement of the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)</measure>
    <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Systolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)</measure>
    <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Diastolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1)</measure>
    <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Respiratory Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1)</measure>
    <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Heart Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1)</measure>
    <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1)</measure>
    <time_frame>At Visit 2 (Day 1): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
    <description>Measured in sub-population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1)</measure>
    <time_frame>At Visit 3 (Day 7): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
    <description>Measured in sub-population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1)</measure>
    <time_frame>At Visit 6 (Day 30): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
    <description>Measured in sub-population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1)</measure>
    <time_frame>At Visit 8 (Day 60): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
    <description>Measured in sub-population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Seronegative Conversion Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen. (Part 2)</measure>
    <time_frame>Up to 4 years after end of treatment</time_frame>
    <description>Measured once per year by two types of assays (recombinant ELISA and IHA) in subjects received at least one dose of 30-day nifurtimox treatment regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Responders With Seronegative Conversion and no Evidence of Cardiomyopathy (Part 2)</measure>
    <time_frame>Up to 4 years after end of treatment</time_frame>
    <description>Seronegative conversion measured by two types of assays (recombinant ELISA and IHA). Cardiomyopathy as evaluated by electrocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titer in Plasma Over Time in All Subjects (Part 2)</measure>
    <time_frame>Up to 4 years after end of treatment</time_frame>
    <description>Measured once per year by recombinant ELISA and total purified antigen ELISA in subjects treated either with the 60- or 30-day nifurtimox treatment regimen.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Subjects Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Using frequencies of matches and mismatches to assess agreement</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Using frequencies of matches and mismatches to assess agreement</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Using frequencies of matches and mismatches to assess agreement</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Sero-reduction is defined as a =&gt; 20% reduction in optical density [OD]) using two conventional ELISA serology tests in subjects =&gt; 8 months to &lt; 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects =&gt; 8 months to &lt; 18 years of age at randomization; or reactive results in subjects &lt; 8 months of age at randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients</measure>
    <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
    <description>Cure is defined as sero-reduction (in subjects =&gt; 8 months to &lt; 18 years of age at randomization) or sero-conversion (in all subjects).
Sero-reduction is defined as a =&gt; 20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G [IgG] concentration measured by two conventional ELISA serology tests.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Chagas Disease</condition>
  <arm_group>
    <arm_group_label>Nifurtimox 60 days / Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifurtimox 30 days / Arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifurtimox (Lampit, BAYA2502)</intervention_name>
    <description>For pediatric subjects with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.
For pediatric subjects with body weight &gt; 40 kg: 8 - 10 mg/kg/day in three divided doses.
60 days of nifurtimox treatment</description>
    <arm_group_label>Nifurtimox 60 days / Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Nifurtimox 30 days / Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1:

          -  Male and female pediatric subjects aged 0 days to younger than 18 years

          -  Chagas' disease diagnosed/ confirmed for a) Subjects &lt; 8 months of age at
             randomization must demonstrate direct observation of Trypanosoma cruzi by
             concentration test; b) Subjects ≥ 8 months to &lt; 18 years of age at randomization must
             demonstrate a positive conventional ELISA result for both recombinant ELISA and total
             purified antigen ELISA

        Part 2:

        - Male and female subjects who were randomized and received at least one dose of their
        assigned 60- or 30-day regimen of nifurtimox treatment

        Exclusion Criteria:

        Part 1:

          -  Subjects aged 0 to 27 days who, at birth, were pre-term, weighed less than 2500 g, or
             had a maximum Apgar score &lt; 7 at 5 minutes

          -  Known evidence of Chagas' disease-related cardiomyopathy/ Chagas' heart disease

          -  Known evidence of Chagas' disease-related gastrointestinal dysfunction (e.g.
             megaoesophagus, megacolon, or both) or Chagas' digestive disease

          -  Serious manifestations of acute Chagas' disease, including myocarditis,
             meningoencephalitis, or pneumonitis

          -  Known evidence of Chagas' disease-related damage to the peripheral nervous system or
             peripheral neuropathy

          -  Clinically significant psychiatric disorder (e.g. moderate to severe depression,
             severe anxiety, or psychosis) or epilepsy

          -  Subjects with contraindications/ warnings to nifurtimox administration, or with
             conditions that may increase the risk of the undesirable effects of nifurtimox

          -  Subjects who have had previous treatment with trypanocidal agents or an accepted
             indication for antiparasitic therapy (e.g. reactivation of Chagas' infection due to
             immunosuppression by several diseases or treatment with steroids)

          -  Subjects living in housing conditions where there is no active or effective vector
             control to Trypanosoma cruzi reinfection as determined by Ministry of Health
             guidelines in each country

        Part 2:

          -  Subjects who after completing nifurtimox treatment require treatment with an
             anti-trypanosomal agent

          -  Subjects living in housing conditions where there is no active or effective
             vector-control to Trypanosoma cruzi reinfection as determined by Ministry of Health
             guideline of the respective country

          -  Subjects with clinical manifestations of Chagas' disease-related gastrointestinal
             dysfunction or serious manifestations of acute Chagas' disease

          -  Immuno-compromised subjects (e.g. with human immunodeficiency virus or treated with
             immunosuppressive drugs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. De Buenos Aires</state>
        <zip>1281</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. De Buenos Aires</state>
        <zip>C1270AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. De Buenos Aires</state>
        <zip>C1425AGP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. De Buenos Aires</state>
        <zip>C1425EFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Salvador de Jujuy</city>
        <state>Jujuy</state>
        <zip>4600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Posadas</city>
        <state>Misiones</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <zip>W3400CBI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Formosa</city>
        <zip>P3600HZL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Rioja</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <zip>5535</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salta</city>
        <zip>4400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salta</city>
        <zip>A4400ESE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago del Estero</city>
        <zip>4202</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cochabamba</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Punata</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tarija</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yopal</city>
        <state>Casanare</state>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Marta</city>
        <state>Magdalena</state>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Floridablanca</city>
        <state>Santander</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bolivia</country>
    <country>Colombia</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <results_reference>
    <citation>Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998 Oct;59(4):526-9.</citation>
    <PMID>9790423</PMID>
  </results_reference>
  <results_reference>
    <citation>de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996 Nov 23;348(9039):1407-13.</citation>
    <PMID>8937280</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <results_first_submitted>July 22, 2019</results_first_submitted>
  <results_first_submitted_qc>October 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2019</results_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifurtimox</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02625974/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02625974/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from 27 JAN 2016 (First subject first visit) to 25 JUL 2018 (End of Part 1 of study) in 18 centers in Argentina, 3 centers in Bolivia and 4 centers in Colombia.</recruitment_details>
      <pre_assignment_details>A total of 371 subjects were screened for randomization. Forty-one (41) subjects were excluded from the study during screening. The 330 subjects who were eligible to participate in the study were randomized in a 2:1 ratio to either a 60-Day or 30-Day regimen with nifurtimox tablets.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nifurtimox 60 Days / Arm 1</title>
          <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
        </group>
        <group group_id="P2">
          <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
          <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>positive parasitemia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nifurtimox 60 Days / Arm 1</title>
          <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
        </group>
        <group group_id="B2">
          <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
          <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="219"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="330"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 to 27 days</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>28 days to younger than 8 months</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 months to younger than 2 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 years to younger than 18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Purified Antigen enzyme-linked immunosorbent assay (ELISA) test results</title>
          <description>Chagas disease diagnosed by direct observation of T. cruzi by concentration test (subjects &lt;8 months of age at randomization) or positive conventional ELISA results for both recombinant ELISA and total purified antigen ELISA (subjects ≥8 months to younger than 18 years of age at randomization) as determined by local laboratory test results were eligible for enrollment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Reactive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Purified Antigen ELISA optical density (OD) values</title>
          <units>No dimension</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.474" spread="0.553"/>
                    <measurement group_id="B2" value="1.532" spread="0.533"/>
                    <measurement group_id="B3" value="1.494" spread="0.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recombinant ELISA test results</title>
          <description>Chagas disease diagnosed by direct observation of T. cruzi by concentration test (subjects &lt;8 months of age at randomization) or positive conventional ELISA results for both recombinant ELISA and total purified antigen ELISA (subjects ≥8 months to younger than 18 years of age at randomization) as determined by local laboratory test results were eligible for enrollment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Reactive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recombinant ELISA OD values</title>
          <units>No dimension</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.735" spread="0.640"/>
                    <measurement group_id="B2" value="2.765" spread="0.605"/>
                    <measurement group_id="B3" value="2.745" spread="0.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non conventional ELISA-F29 test results</title>
          <description>The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non Reactive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concentration test for T. cruz</title>
          <description>Chagas disease diagnosed by direct observation of T. cruzi by concentration test (subjects &lt;8 months of age at randomization) or positive conventional ELISA results for both recombinant ELISA and total purified antigen ELISA (subjects ≥8 months to younger than 18 years of age at randomization) as determined by local laboratory test results were eligible for enrollment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Cured</title>
        <description>Cure is defined as sero-reduction (in subjects ≥8 months to &lt;18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a ≥20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.
Subjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).
For the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs from the two publications.</description>
        <time_frame>At 12 months post-treatment</time_frame>
        <population>Full Analysis Set (FAS). The primary analyses of efficacy, safety, and background data were performed using the full analysis set (FAS). The FAS was defined as subjects who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Cured</title>
          <description>Cure is defined as sero-reduction (in subjects ≥8 months to &lt;18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a ≥20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.
Subjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).
For the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs from the two publications.</description>
          <population>Full Analysis Set (FAS). The primary analyses of efficacy, safety, and background data were performed using the full analysis set (FAS). The FAS was defined as subjects who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" lower_limit="26.4" upper_limit="39.3"/>
                    <measurement group_id="O2" value="18.9" lower_limit="11.2" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Historical Cure Rates for Placebo
Publication 1: De Andrade et al 1996. Age range (years): 7-12. Sero-conversion rate (95% CI) in placebo patients: 3/65 = 5% (1%, 13%)
Publication 2: Sosa et al 1998. Age range (years): 6-12. Sero-conversion rate (95% CI) in placebo patients: 2/44 = 5% (1%, 16%).
CI = confidence interval</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A direct comparison</non_inferiority_desc>
            <param_type>Difference in cure rate</param_type>
            <param_value>14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.7</ci_lower_limit>
            <ci_upper_limit>24.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Seronegative Conversion for Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.(Part 2)</title>
        <description>Seronegative conversion measured by two types of assay (recombinant ELISA and indirect hemagglutination assay [IHA]) in subjects who were randomized and received at least one dose of the 60-day nifurtimox treatment regimen.</description>
        <time_frame>Up to 4 years after end of treatment</time_frame>
        <posting_date>08/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1</title>
        <description>The evaluation was based on clinical examinations.</description>
        <time_frame>At Visit 1 (before treatment started)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1</title>
          <description>The evaluation was based on clinical examinations.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3</title>
        <description>The evaluation was based on clinical examinations.</description>
        <time_frame>Up to 7 days (Visit 3)</time_frame>
        <population>Number of participants available at each visit</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3</title>
          <description>The evaluation was based on clinical examinations.</description>
          <population>Number of participants available at each visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chagas disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatomegaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Known ECG abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6</title>
        <description>The evaluation was based on clinical examinations.</description>
        <time_frame>Up to 30 days (Visit 6)</time_frame>
        <population>Number of participants available at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6</title>
          <description>The evaluation was based on clinical examinations.</description>
          <population>Number of participants available at each visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Known ECG abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romana sign</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8</title>
        <description>The evaluation was based on clinical examinations.</description>
        <time_frame>Up to 60 days (Visit 8) end of treatment</time_frame>
        <population>Number of participants available at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8</title>
          <description>The evaluation was based on clinical examinations.</description>
          <population>Number of participants available at each visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chagas disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Known ECG abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphadenopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9</title>
        <description>The evaluation was based on clinical examinations.</description>
        <time_frame>Up to 90 days (Visit 9) post treatment</time_frame>
        <population>Number of participants available at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9</title>
          <description>The evaluation was based on clinical examinations.</description>
          <population>Number of participants available at each visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10</title>
        <description>The evaluation was based on clinical examinations.</description>
        <time_frame>Up to 240 days (Visit 10) post treatment</time_frame>
        <population>Number of participants available at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10</title>
          <description>The evaluation was based on clinical examinations.</description>
          <population>Number of participants available at each visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11</title>
        <description>The evaluation was based on clinical examinations.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Number of participants available at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11</title>
          <description>The evaluation was based on clinical examinations.</description>
          <population>Number of participants available at each visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects &lt;8 Months of Age)</title>
        <time_frame>Up to 90 days (Visit 9) post-treatment</time_frame>
        <population>Subjects from FAS who were below 8 months of age at randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects &lt;8 Months of Age)</title>
          <population>Subjects from FAS who were below 8 months of age at randomization</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9</title>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test</title>
        <description>The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test</title>
          <description>The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10</title>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11</title>
              <category_list>
                <category>
                  <title>Reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-reactive</title>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results</title>
        <description>The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results</title>
          <description>The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <category_list>
                <category>
                  <title>Non-detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <category_list>
                <category>
                  <title>Non-detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <category_list>
                <category>
                  <title>Non-detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <title>Non-detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10</title>
              <category_list>
                <category>
                  <title>Non-detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11</title>
              <category_list>
                <category>
                  <title>Non-detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="205"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Detectable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</title>
        <description>TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</title>
          <description>TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1)</title>
        <description>The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects with missing or high abnormal values at baseline are not included in the number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1)</title>
          <description>The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
          <population>Subjects with missing or high abnormal values at baseline are not included in the number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (g/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein (g/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1)</title>
        <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects with missing or low abnormal values at baseline are not included in the number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1)</title>
          <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
          <population>Subjects with missing or low abnormal values at baseline are not included in the number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (g/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase (U/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="160"/>
                    <count group_id="O2" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mg/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein (g/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1)</title>
        <description>The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects with missing or high abnormal values at baseline are not included in the number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1)</title>
          <description>The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
          <population>Subjects with missing or high abnormal values at baseline are not included in the number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (g/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes (T/L) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. Mean Corpuscular Volume (fL) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. Mean Corpuscular Hemoglobin (pg) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. Mean Corpuscular HGB Conc. (g/dL) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (GIGA/L) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="72"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (GIGA/L) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1)</title>
        <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects with missing or low abnormal values at baseline are not included in the number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1)</title>
          <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
          <population>Subjects with missing or low abnormal values at baseline are not included in the number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (g/dL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes (T/L) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. Mean Corpuscular Volume (fL) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. Mean Corpuscular Hemoglobin (pg) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. Mean Corpuscular HGB Conc. (g/dL) in Blood *</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (GIGA/L) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes (%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (GIGA/L)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (GIGA/L) in Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1)</title>
        <description>The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects with missing or high abnormal values at baseline are not included in the number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1)</title>
          <description>The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline.</description>
          <population>Subjects with missing or high abnormal values at baseline are not included in the number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prothrombin Time (sec) in Plasma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activated Partial Thromboplastin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time in Plasma Prothrombin Intl. Normalized Ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1)</title>
        <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects with missing or low abnormal values at baseline are not included in the number analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1)</title>
          <description>The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.
The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline.</description>
          <population>Subjects with missing or low abnormal values at baseline are not included in the number analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prothrombin Time (sec) in Plasma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activated Partial Thromboplastin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time in Plasma Prothrombin Intl. Normalized Ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Number of subjects</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)</title>
        <description>Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin β, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)</title>
          <description>Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin β, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Abnormal urinalysis findings</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1)</title>
        <description>Clinical significance of abnormal ECG was based on the judgement of the investigator</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1)</title>
          <description>Clinical significance of abnormal ECG was based on the judgement of the investigator</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Abnormal ECG findings</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)</title>
        <description>Systolic Blood Pressure</description>
        <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)</title>
          <description>Systolic Blood Pressure</description>
          <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VISIT 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="7.79"/>
                    <measurement group_id="O2" value="0.69" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.75" spread="7.50"/>
                    <measurement group_id="O2" value="-5.00" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="9.98"/>
                    <measurement group_id="O2" value="-0.50" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="10.70"/>
                    <measurement group_id="O2" value="-1.12" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="11.01"/>
                    <measurement group_id="O2" value="0.48" spread="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="11.11"/>
                    <measurement group_id="O2" value="-0.45" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="10.46"/>
                    <measurement group_id="O2" value="-1.48" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="11.52"/>
                    <measurement group_id="O2" value="1.57" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)</title>
        <description>Diastolic Blood Pressure</description>
        <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)</title>
          <description>Diastolic Blood Pressure</description>
          <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VISIT 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="7.72"/>
                    <measurement group_id="O2" value="0.90" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="2.50"/>
                    <measurement group_id="O2" value="-1.00" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="8.36"/>
                    <measurement group_id="O2" value="0.26" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="10.87"/>
                    <measurement group_id="O2" value="-0.14" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="9.91"/>
                    <measurement group_id="O2" value="0.93" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="8.81"/>
                    <measurement group_id="O2" value="-0.21" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="9.90"/>
                    <measurement group_id="O2" value="0.85" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="11.06"/>
                    <measurement group_id="O2" value="3.25" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1)</title>
        <description>Respiratory Rate</description>
        <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1)</title>
          <description>Respiratory Rate</description>
          <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
          <units>BREATHS/MIN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VISIT 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="4.10"/>
                    <measurement group_id="O2" value="0.47" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="3.42"/>
                    <measurement group_id="O2" value="-1.00" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="3.15"/>
                    <measurement group_id="O2" value="-0.14" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="4.16"/>
                    <measurement group_id="O2" value="-0.06" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="4.04"/>
                    <measurement group_id="O2" value="0.04" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="4.06"/>
                    <measurement group_id="O2" value="-0.50" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="4.50"/>
                    <measurement group_id="O2" value="-0.24" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="5.10"/>
                    <measurement group_id="O2" value="-0.74" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1)</title>
        <description>Heart Rate</description>
        <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1)</title>
          <description>Heart Rate</description>
          <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
          <units>BEATS/MIN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VISIT 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="10.19"/>
                    <measurement group_id="O2" value="0.26" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.75" spread="2.22"/>
                    <measurement group_id="O2" value="-0.75" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="10.11"/>
                    <measurement group_id="O2" value="-0.51" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="11.49"/>
                    <measurement group_id="O2" value="-0.75" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="11.65"/>
                    <measurement group_id="O2" value="-1.34" spread="11.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="11.97"/>
                    <measurement group_id="O2" value="-1.63" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.28" spread="11.87"/>
                    <measurement group_id="O2" value="-3.28" spread="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.57" spread="12.57"/>
                    <measurement group_id="O2" value="-4.66" spread="14.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1)</title>
        <description>Temperature</description>
        <time_frame>Baseline and up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1)</title>
          <description>Temperature</description>
          <population>Number analyzed signifies subjects who were evaluable for the specified parameter for each treatment regimen, respectively.</population>
          <units>°C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VISIT 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.39"/>
                    <measurement group_id="O2" value="0.04" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.45"/>
                    <measurement group_id="O2" value="-0.03" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.36"/>
                    <measurement group_id="O2" value="0.04" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.44"/>
                    <measurement group_id="O2" value="0" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.45"/>
                    <measurement group_id="O2" value="0.05" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.44"/>
                    <measurement group_id="O2" value="0.02" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.49"/>
                    <measurement group_id="O2" value="-0.01" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VISIT 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.51"/>
                    <measurement group_id="O2" value="-0.10" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1)</title>
        <description>Measured in sub-population.</description>
        <time_frame>At Visit 2 (Day 1): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
        <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 63 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1)</title>
          <description>Measured in sub-population.</description>
          <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 63 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
          <units>ug/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="26.8">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - 10 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="154.8">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ..</measurement>
                    <measurement group_id="O2" value="21.1" lower_limit="NA" upper_limit="695.0">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - 120 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" lower_limit="5.8" upper_limit="847.5"/>
                    <measurement group_id="O2" value="49.0" lower_limit="NA" upper_limit="524.3">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - 4 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.4" lower_limit="77.9" upper_limit="516.3"/>
                    <measurement group_id="O2" value="300.7" lower_limit="106.9" upper_limit="533.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - 8 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.6" lower_limit="40.2" upper_limit="508.1"/>
                    <measurement group_id="O2" value="289.6" lower_limit="103.2" upper_limit="301.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1)</title>
        <description>Measured in sub-population.</description>
        <time_frame>At Visit 3 (Day 7): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
        <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 62 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1)</title>
          <description>Measured in sub-population.</description>
          <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 62 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
          <units>ug/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="NA" upper_limit="407.6">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                    <measurement group_id="O2" value="38.3" lower_limit="NA" upper_limit="472.3">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - 10 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="NA" upper_limit="561.6">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                    <measurement group_id="O2" value="56.0" lower_limit="NA" upper_limit="442.8">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - 120 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.6" lower_limit="13.8" upper_limit="1035.6"/>
                    <measurement group_id="O2" value="232.3" lower_limit="13.9" upper_limit="706.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - 4 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497.2" lower_limit="57.1" upper_limit="1027.4"/>
                    <measurement group_id="O2" value="257.7" lower_limit="46.3" upper_limit="660.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - 8 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427.5" lower_limit="141.2" upper_limit="778.2"/>
                    <measurement group_id="O2" value="267.0" lower_limit="NA" upper_limit="339.6">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1)</title>
        <description>Measured in sub-population.</description>
        <time_frame>At Visit 6 (Day 30): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
        <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 59 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1)</title>
          <description>Measured in sub-population.</description>
          <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 59 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
          <units>ug/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="NA" upper_limit="459.3">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                    <measurement group_id="O2" value="40.8" lower_limit="NA" upper_limit="284.3">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - 10 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="NA" upper_limit="153.7">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                    <measurement group_id="O2" value="73.7" lower_limit="NA" upper_limit="266.7">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - 120 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.0" lower_limit="NA" upper_limit="932.4">NA displayed in full range means the value was below the lower limit of quantification.
Values below LLOQ were substituted by 1/2 LLOQ for the calculation of statistics (LLOQ = 5, 10, 20, 25, 50).</measurement>
                    <measurement group_id="O2" value="172.7" lower_limit="14.1" upper_limit="387.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - 4 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369.5" lower_limit="92.1" upper_limit="1277.0"/>
                    <measurement group_id="O2" value="103.8" lower_limit="12.3" upper_limit="1107.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - 8 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.7" lower_limit="70.9" upper_limit="504.3"/>
                    <measurement group_id="O2" value="165.2" lower_limit="84.9" upper_limit="1089.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1)</title>
        <description>Measured in sub-population.</description>
        <time_frame>At Visit 8 (Day 60): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours</time_frame>
        <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 59 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment)</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
            <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1)</title>
          <description>Measured in sub-population.</description>
          <population>Blood samples for pharmacokinetic parameters ware optional and required consent/assent of the subject/subject’s legally authorized representative(s). A total of 59 subjects contributed blood samples for the analysis.
Number analyzed signifies subjects who were evaluable for the specified parameter at each time point, respectively.</population>
          <units>ug/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="258.7">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - 10 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" lower_limit="15.9" upper_limit="255.1"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 - 120 MIN POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.1" lower_limit="23.6" upper_limit="711.4"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="21.5">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - 4 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.6" lower_limit="166.9" upper_limit="883.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - 8 HOURS POST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.6" lower_limit="28.5" upper_limit="1217.2"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA in Median means not calculated. Calculation of Median was based on 2/3-rule, i.e. at least 67% of the subjects had to be higher or equal to the lower limit of quantification (LLOQ). NA in full range means the value was below LLOQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Seronegative Conversion Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen. (Part 2)</title>
        <description>Measured once per year by two types of assays (recombinant ELISA and IHA) in subjects received at least one dose of 30-day nifurtimox treatment regimen.</description>
        <time_frame>Up to 4 years after end of treatment</time_frame>
        <posting_date>08/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Responders With Seronegative Conversion and no Evidence of Cardiomyopathy (Part 2)</title>
        <description>Seronegative conversion measured by two types of assays (recombinant ELISA and IHA). Cardiomyopathy as evaluated by electrocardiogram.</description>
        <time_frame>Up to 4 years after end of treatment</time_frame>
        <posting_date>08/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Titer in Plasma Over Time in All Subjects (Part 2)</title>
        <description>Measured once per year by recombinant ELISA and total purified antigen ELISA in subjects treated either with the 60- or 30-day nifurtimox treatment regimen.</description>
        <time_frame>Up to 4 years after end of treatment</time_frame>
        <posting_date>08/2022</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)</title>
        <description>This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days / Arm 1</title>
            <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 – 60, active nifurtimox treatment), 1-year follow-up data</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)</title>
          <description>This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>Historical Benznidazole 1998, publication from Sosa Estani et al. (1998), 4-year follow-up data.
Number Analyzed: 53 Number Cured: 4 Cure rate: 7.5%
Historical Benznidazole 1996, publication from de Andrade et al. (1996), 3-year follow-up data.
Number Analyzed: 64 Number Cured: 4 Cure rate: 6.25%</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit (Part 1)</title>
        <description>Using frequencies of matches and mismatches to assess agreement</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects who have both testing missed are excluded in the Number Analyzed in each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days Reactive Detectable</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and Detectable qPCR</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 60 Days Reactive Non-detectable</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and Non-detectable qPCR</description>
          </group>
          <group group_id="O3">
            <title>Nifurtimox 60 Days Non-reactive Detectable</title>
            <description>Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Detectable qPCR</description>
          </group>
          <group group_id="O4">
            <title>Nifurtimox 60 Days Non-reactive Non-detectable</title>
            <description>Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Non-detectable qPCR</description>
          </group>
          <group group_id="O5">
            <title>Nifurtimox 60 Days Reactive Non Evaluable</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and Non evaluable qPCR</description>
          </group>
          <group group_id="O6">
            <title>Nifurtimox 60 Days Reactive qPCR Missing</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and missing qPCR</description>
          </group>
          <group group_id="O7">
            <title>Nifurtimox 30 Days Reactive Detectable</title>
            <description>Nifurtimox 30 days with Reactive Conventional Serologic Testing and Detectable qPCR</description>
          </group>
          <group group_id="O8">
            <title>Nifurtimox 30 Days Reactive Non-detectable</title>
            <description>Nifurtimox 30 days with Reactive Conventional Serologic Testing and Non-detectable qPCR</description>
          </group>
          <group group_id="O9">
            <title>Nifurtimox 30 Days Non-reactive Detectable</title>
            <description>Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Detectable qPCR</description>
          </group>
          <group group_id="O10">
            <title>Nifurtimox 30 Days Non-reactive Non-detectable</title>
            <description>Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Non-detectable qPCR</description>
          </group>
          <group group_id="O11">
            <title>Nifurtimox 30 Days Reactive Non Evaluable</title>
            <description>Nifurtimox 30 days with Reactive Conventional Serologic Testing and Non evaluable qPCR</description>
          </group>
          <group group_id="O12">
            <title>Nifurtimox 30 Days Missing Conventional Testing Non-detectable</title>
            <description>Nifurtimox 30 days with missing Conventional Serologic Testing and Non-detectable qPCR</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit (Part 1)</title>
          <description>Using frequencies of matches and mismatches to assess agreement</description>
          <population>Subjects who have both testing missed are excluded in the Number Analyzed in each arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="219"/>
                <count group_id="O6" value="219"/>
                <count group_id="O7" value="111"/>
                <count group_id="O8" value="111"/>
                <count group_id="O9" value="111"/>
                <count group_id="O10" value="111"/>
                <count group_id="O11" value="111"/>
                <count group_id="O12" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="219"/>
                    <count group_id="O4" value="219"/>
                    <count group_id="O5" value="219"/>
                    <count group_id="O6" value="219"/>
                    <count group_id="O7" value="111"/>
                    <count group_id="O8" value="111"/>
                    <count group_id="O9" value="111"/>
                    <count group_id="O10" value="111"/>
                    <count group_id="O11" value="111"/>
                    <count group_id="O12" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="57"/>
                    <measurement group_id="O8" value="52"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="215"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="215"/>
                    <count group_id="O6" value="215"/>
                    <count group_id="O7" value="108"/>
                    <count group_id="O8" value="108"/>
                    <count group_id="O9" value="108"/>
                    <count group_id="O10" value="108"/>
                    <count group_id="O11" value="108"/>
                    <count group_id="O12" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="103"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="211"/>
                    <count group_id="O5" value="211"/>
                    <count group_id="O6" value="211"/>
                    <count group_id="O7" value="109"/>
                    <count group_id="O8" value="109"/>
                    <count group_id="O9" value="109"/>
                    <count group_id="O10" value="109"/>
                    <count group_id="O11" value="109"/>
                    <count group_id="O12" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="195"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="99"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="210"/>
                    <count group_id="O4" value="210"/>
                    <count group_id="O5" value="210"/>
                    <count group_id="O6" value="210"/>
                    <count group_id="O7" value="108"/>
                    <count group_id="O8" value="108"/>
                    <count group_id="O9" value="108"/>
                    <count group_id="O10" value="108"/>
                    <count group_id="O11" value="108"/>
                    <count group_id="O12" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="96"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)</title>
        <description>Using frequencies of matches and mismatches to assess agreement</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects who have testing missed are excluded in the Number Analyzed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days Reactive and Reactive</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 60 Days Reactive and Non-reactive</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O3">
            <title>Nifurtimox 60 Days Non-reactive and Reactive</title>
            <description>Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O4">
            <title>Nifurtimox 60 Days Non-reactive and Non-reactive</title>
            <description>Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O5">
            <title>Nifurtimox 30 Days Reactive and Reactive</title>
            <description>Nifurtimox 30 days with Reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O6">
            <title>Nifurtimox 30 Days Reactive and Non-reactive</title>
            <description>Nifurtimox 30 days with Reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O7">
            <title>Nifurtimox 30 Days Non-reactive and Reactive</title>
            <description>Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O8">
            <title>Nifurtimox 30 Days Non-reactive and Non-reactive</title>
            <description>Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)</title>
          <description>Using frequencies of matches and mismatches to assess agreement</description>
          <population>Subjects who have testing missed are excluded in the Number Analyzed at each visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="111"/>
                <count group_id="O6" value="111"/>
                <count group_id="O7" value="111"/>
                <count group_id="O8" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="219"/>
                    <count group_id="O4" value="219"/>
                    <count group_id="O5" value="111"/>
                    <count group_id="O6" value="111"/>
                    <count group_id="O7" value="111"/>
                    <count group_id="O8" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="72"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="218"/>
                    <count group_id="O3" value="218"/>
                    <count group_id="O4" value="218"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="108"/>
                    <count group_id="O7" value="108"/>
                    <count group_id="O8" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="214"/>
                    <count group_id="O3" value="214"/>
                    <count group_id="O4" value="214"/>
                    <count group_id="O5" value="110"/>
                    <count group_id="O6" value="110"/>
                    <count group_id="O7" value="110"/>
                    <count group_id="O8" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="42"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="215"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="107"/>
                    <count group_id="O6" value="107"/>
                    <count group_id="O7" value="107"/>
                    <count group_id="O8" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="211"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="109"/>
                    <count group_id="O7" value="109"/>
                    <count group_id="O8" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="42"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="210"/>
                    <count group_id="O4" value="210"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="108"/>
                    <count group_id="O7" value="108"/>
                    <count group_id="O8" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)</title>
        <description>Using frequencies of matches and mismatches to assess agreement</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects who have testing missed are excluded in the Number Analyzed at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Nifurtimox 60 Days Reactive and Reactive</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O2">
            <title>Nifurtimox 60 Days Reactive and Non-reactive</title>
            <description>Nifurtimox 60 days with Reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O3">
            <title>Nifurtimox 60 Days Non-reactive and Reactive</title>
            <description>Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O4">
            <title>Nifurtimox 60 Days Non-reactive and Non-reactive</title>
            <description>Nifurtimox 60 days with Non-reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O5">
            <title>Nifurtimox 30 Days Reactive and Reactive</title>
            <description>Nifurtimox 30 days with Reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O6">
            <title>Nifurtimox 30 Days Reactive and Non-reactive</title>
            <description>Nifurtimox 30 days with Reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O7">
            <title>Nifurtimox 30 Days Non-reactive and Reactive</title>
            <description>Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Reactive Non-conventional Serologic Testing</description>
          </group>
          <group group_id="O8">
            <title>Nifurtimox 30 Days Non-reactive and Non-reactive</title>
            <description>Nifurtimox 30 days with Non-reactive Conventional Serologic Testing and Non-reactive Non-conventional Serologic Testing</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)</title>
          <description>Using frequencies of matches and mismatches to assess agreement</description>
          <population>Subjects who have testing missed are excluded in the Number Analyzed at each visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="219"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="111"/>
                <count group_id="O6" value="111"/>
                <count group_id="O7" value="111"/>
                <count group_id="O8" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="219"/>
                    <count group_id="O4" value="219"/>
                    <count group_id="O5" value="111"/>
                    <count group_id="O6" value="111"/>
                    <count group_id="O7" value="111"/>
                    <count group_id="O8" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="72"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="218"/>
                    <count group_id="O2" value="218"/>
                    <count group_id="O3" value="218"/>
                    <count group_id="O4" value="218"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="108"/>
                    <count group_id="O7" value="108"/>
                    <count group_id="O8" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="214"/>
                    <count group_id="O3" value="214"/>
                    <count group_id="O4" value="214"/>
                    <count group_id="O5" value="110"/>
                    <count group_id="O6" value="110"/>
                    <count group_id="O7" value="110"/>
                    <count group_id="O8" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="42"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="215"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="107"/>
                    <count group_id="O6" value="107"/>
                    <count group_id="O7" value="107"/>
                    <count group_id="O8" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="211"/>
                    <count group_id="O4" value="211"/>
                    <count group_id="O5" value="109"/>
                    <count group_id="O6" value="109"/>
                    <count group_id="O7" value="109"/>
                    <count group_id="O8" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="59"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="210"/>
                    <count group_id="O4" value="210"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="108"/>
                    <count group_id="O7" value="108"/>
                    <count group_id="O8" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="48"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results</title>
        <description>Sero-reduction is defined as a =&gt; 20% reduction in optical density [OD]) using two conventional ELISA serology tests in subjects =&gt; 8 months to &lt; 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects =&gt; 8 months to &lt; 18 years of age at randomization; or reactive results in subjects &lt; 8 months of age at randomization.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects who have both testing missed are excluded in the Overall Number of Participants Analyzed and Number Analyzed in each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-reactive ELISA and Non-reactive IHA</title>
            <description>ELISA results: Non-reactive IHA results: Non-reactive</description>
          </group>
          <group group_id="O2">
            <title>Non-reactive ELISA and Reactive IHA Decrease</title>
            <description>ELISA results: Non-reactive IHA results: reactive with decreasing in titers</description>
          </group>
          <group group_id="O3">
            <title>Non-react ELISA and React IHA Nochange</title>
            <description>ELISA results: Non-reactive IHA results: reactive without change in titers</description>
          </group>
          <group group_id="O4">
            <title>Reactive ELISA: Sero-reduction and Non-react IHA</title>
            <description>ELISA results: reactive, Sero-reduction IHA results: Non-reactive</description>
          </group>
          <group group_id="O5">
            <title>Reactive ELISA: Sero Reduction and Reactive IHA Decrease</title>
            <description>ELISA results: reactive, Sero-reduction IHA results: reactive with decreasing in titers</description>
          </group>
          <group group_id="O6">
            <title>Reactive ELISA: Sero-reduction and Reactive IHA Nochange</title>
            <description>ELISA results: reactive, Sero-reduction IHA results: reactive without Change in titers</description>
          </group>
          <group group_id="O7">
            <title>Reactive ELISA: Others and Non-reactive IHA</title>
            <description>ELISA results: reactive, Others IHA results: Non-reactive</description>
          </group>
          <group group_id="O8">
            <title>Reactive ELISA: Others and React IHA Decrease</title>
            <description>ELISA results: reactive, Other IHA: reactive with decreasing in titers</description>
          </group>
          <group group_id="O9">
            <title>Reactive ELISA: Others and React IHA Nochange</title>
            <description>ELISA results: reactive, Other IHA results: reactive without Change in titers</description>
          </group>
          <group group_id="O10">
            <title>Reactive ELISA: Others and Missing IHA</title>
            <description>ELISA results: reactive, Others IHA results: Missing</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results</title>
          <description>Sero-reduction is defined as a =&gt; 20% reduction in optical density [OD]) using two conventional ELISA serology tests in subjects =&gt; 8 months to &lt; 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects =&gt; 8 months to &lt; 18 years of age at randomization; or reactive results in subjects &lt; 8 months of age at randomization.</description>
          <population>Subjects who have both testing missed are excluded in the Overall Number of Participants Analyzed and Number Analyzed in each arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="318"/>
                <count group_id="O4" value="318"/>
                <count group_id="O5" value="318"/>
                <count group_id="O6" value="318"/>
                <count group_id="O7" value="318"/>
                <count group_id="O8" value="318"/>
                <count group_id="O9" value="318"/>
                <count group_id="O10" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nifurtimox 60 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="210"/>
                    <count group_id="O4" value="210"/>
                    <count group_id="O5" value="210"/>
                    <count group_id="O6" value="210"/>
                    <count group_id="O7" value="210"/>
                    <count group_id="O8" value="210"/>
                    <count group_id="O9" value="210"/>
                    <count group_id="O10" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="60"/>
                    <measurement group_id="O9" value="76"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nifurtimox 30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="108"/>
                    <count group_id="O5" value="108"/>
                    <count group_id="O6" value="108"/>
                    <count group_id="O7" value="108"/>
                    <count group_id="O8" value="108"/>
                    <count group_id="O9" value="108"/>
                    <count group_id="O10" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="37"/>
                    <measurement group_id="O9" value="49"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients</title>
        <description>Cure is defined as sero-reduction (in subjects =&gt; 8 months to &lt; 18 years of age at randomization) or sero-conversion (in all subjects).
Sero-reduction is defined as a =&gt; 20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G [IgG] concentration measured by two conventional ELISA serology tests.</description>
        <time_frame>Up to 420 days (Visit 11) post-treatment</time_frame>
        <population>Subjects who have both testing missed are excluded in the Overall Number of Participants Analyzed and Number Analyzed in each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Cure and Non Reactive/Reactive Decreasing</title>
            <description>Elisa results: Cure IHA results: Non reactive or reactive but decreasing in titer</description>
          </group>
          <group group_id="O2">
            <title>Cure and Reactive Non-decreasing</title>
            <description>Elisa results: Cure IHA results: reactive but non-decreasing in titer</description>
          </group>
          <group group_id="O3">
            <title>No Cure and Non Reactive/Reactive Decreasing</title>
            <description>Elisa results: No Cure IHA results: Non reactive or reactive but decreasing in titer</description>
          </group>
          <group group_id="O4">
            <title>No Cure and Reactive Non-decreasing</title>
            <description>Elisa results: No Cure IHA results: reactive but non-decreasing in titer</description>
          </group>
          <group group_id="O5">
            <title>No Cure and Missing IHA Testing</title>
            <description>Elisa results: No Cure IHA results: Missing</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients</title>
          <description>Cure is defined as sero-reduction (in subjects =&gt; 8 months to &lt; 18 years of age at randomization) or sero-conversion (in all subjects).
Sero-reduction is defined as a =&gt; 20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G [IgG] concentration measured by two conventional ELISA serology tests.</description>
          <population>Subjects who have both testing missed are excluded in the Overall Number of Participants Analyzed and Number Analyzed in each arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="318"/>
                <count group_id="O4" value="318"/>
                <count group_id="O5" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nifurtimox 60 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="210"/>
                    <count group_id="O4" value="210"/>
                    <count group_id="O5" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nifurtimox 30 days</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="108"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="108"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first application of study drug up to and including 7 days after last application of study drug</time_frame>
      <desc>Treatment-emergent AEs are events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug</desc>
      <group_list>
        <group group_id="E1">
          <title>Nifurtimox 60 Days / Arm 1</title>
          <description>Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)</description>
        </group>
        <group group_id="E2">
          <title>Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2</title>
          <description>Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 – 30, active nifurtimox treatment; Days 31 – 60, placebo)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="15" subjects_at_risk="219"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="219"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="56" subjects_affected="32" subjects_at_risk="219"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="219"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="219"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="41" subjects_affected="28" subjects_at_risk="219"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Abnormal findings on neurological examination by physical examination after Screening will be documented as AEs.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <phone>1-888-8422937</phone>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

